10-Q quarterly report · filed Nov 10, 2026

TriSalus Life Sciences, Inc. (TLSI) Q3 2026 10-Q Quarterly Report

Short answer

TriSalus Life Sciences, Inc. (TLSI) filed its Q3 2026 10-Q quarterly report on Nov 10, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $13M (up 11.3% year over year) with net income of −$9M.

Q3 2026 key financials · XBRL

Revenue
$13M
+11.3% YoY · +12.9% QoQ
Net income
−$9M
+18.1% YoY · +3.6% QoQ
Operating margin
-59.9%
Gross margin
86.2%
EPS (diluted)
−$0.15
+86.0% YoY · +11.8% QoQ

Source: XBRL data from the TriSalus Life Sciences, Inc. (TLSI) Q3 2026 10-Q on SEC EDGAR. USD.

TriSalus Life Sciences, Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Q3 revenue $12.878M, up 11.3% YoY from $11.566M, driven by higher TriNav unit sales
  • Gross margin 86.2% vs 83.5% YoY, with gross profit $11.095M vs $9.660M
  • Sole TriNav product line, revenue growth driven by increased units and lower per-unit costs
  • Cash $41.1M vs $20.4M at December 31, 2025, with nine-month operating cash use $21.884M
  • $42.6M net public-offering proceeds, ongoing operating losses and need for additional capital highlighted as headwinds

Risk Factors

  • No material changes from the December 31, 2025 Form 10-K risk factors
  • Continued clinical-development risk, potential delays or unfavorable trial outcomes
  • Continued regulatory risk, failure to obtain or maintain required approvals
  • Continued liquidity risk, need for additional financing to support operations
  • Continued commercialization risk, limited market acceptance of TriSalus products

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other TriSalus Life Sciences, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.